Chief Scientific OfficerMichele Stone is Chief Scientific Officer at Kriya. Michele joined Kriya from Axovant Gene Therapies, where she was Vice President of Early Development and Head of Nonclinical and Bioanalytical. Prior to Axovant Gene Therapies, Michele was Executive Director of Vaccine Development and Bioanalytical at Liquidia Technologies. She was also the Director of R&D at Aeras where she was responsible for developing and leading partnerships to advance multiple vaccine platforms (viral vector, protein, and nucleic acid) into and through clinical development. In addition, Michele was a Senior Scientist at Canon US Life Sciences where she contributed to the development of diagnostics targeted towards personalized medicine. She received her PhD in biochemistry and molecular biology and completed her postdoctoral fellowship in physiology and neuroscience at the University of Maryland, Baltimore. Michele received her undergraduate degree in chemistry at Lynchburg College.